Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?

被引：14

作者：

Katsiki, Niki ^{[1
]}

Christou, Georgios A. ^{[2
]}

Kiortsis, Dimitrios N. ^{[2
]}

机构：

[1] Aristotle Univ Thessaloniki, Sch Med, Propedeut Dept Internal Med 2, GR-54006 Thessaloniki, Greece

[2] Univ Ioannina, Sch Med, Lab Physiol, GR-45110 Ioannina, Greece

来源：

CURRENT VASCULAR PHARMACOLOGY | 2016年 / 14卷 / 01期

关键词：

FATTY LIVER-DISEASE; LIPOPROTEIN LDL SUBCLASSES; CHRONIC KIDNEY-DISEASE; CLINICAL-SIGNIFICANCE; CARDIOVASCULAR RISK; METABOLIC SYNDROME; HEART-RATE; DIABETES-MELLITUS; EUROPEAN PANEL; WEIGHT-LOSS;

D O I：

10.2174/157016111401151126161741

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：76 / 79

页数：4